Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.
If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.On the evening of December 10th, Google released a new generation of quantum computing chip Willow, which caused a great sensation in the global scientific and technological community. It is reported that this is a major breakthrough in the field of quantum computing-this field is regarded as the next technological frontier of many technology companies.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".
Federal Reserve's December OutlookDizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".The latest news of personal pension fund, incremental funds are coming!